Drugs / AZD8835
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02260661 | Nov 2014 → Jul 2016 | estrogen-receptor positive breast cancer, high grade malignant neoplasm | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD 8835 | “AZD 8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components” NCT02260661 ↗ |
| Action | Inhibit | “inhibits cancer progression by blocking PI3 kinase pathway components” NCT02260661 ↗ |
| Modality | Small molecule | “AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components” NCT02260661 ↗ |
| Route | Oral | “oral formulation of AZD8835” NCT02260661 ↗ |